🔍

Jeevan Scientific Technology Ltd (538837)

📊 BSE: 538837 🏢 Healthcare Research, Analytics & Technology 📢 Latest filing: 01 Oct 2026 📝 Analysis written: 13 Nov 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, Jeevan Scientific's revenue was ₹18.3 Cr (+107.7% year on year, -14.1% on the previous quarter), and net profit ₹0.9 Cr (against a loss a year earlier); the operating margin was 16.2%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹18.3	+107.7%	-14.1%
Operating profit	₹3.0	from loss	-31.2%
Net profit	₹0.9	from loss	-52.7%
Operating margin	16.2%	—	—

Full quarterly financials → Results calendar →

📢 Recent Corporate Announcements

US FDA Closes Inspection with Zero Form 483 Observations for Jeevan Scientific

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 01 Oct 2026, 02:35 PM

Jeevan Scientific Technology received an Establishment Inspection Report (EIR) from the US FDA on September 30, 2026, officially closing its regulatory inspection. The inspection covered its Bioanalytical Facility at Manikonda, Hyderabad, between July 20, 2026, and July 24, 2026. The facility received zero observations (Zero 483s), successfully concluding the review under 21 CFR 20.64(d)(3). For a small CRO with TTM revenue of ₹71 Cr, clean US FDA clearance removes compliance overhang for US-bound bioanalytical studies.

Received US FDA Establishment Inspection Report (EIR) on September 30, 2026
Inspection concluded with zero Form 483 observations
Facility inspected: Bioanalytical Facility at Manikonda, Hyderabad
Audit duration: July 20, 2026 to July 24, 2026

💡 Track whether this clean regulatory clearance accelerates order inflows and revenue growth from US clients in upcoming quarterly earnings reports.

Jeevan Scientific Tech Schedules 28th AGM on Sep 25, 2026; Sets Sep 18 Cut-Off Date

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 03 Sep 2026, 07:34 PM

Jeevan Scientific Technology Limited has announced the schedule for its 28th Annual General Meeting (AGM) to be held on September 25, 2026, at 10:00 AM via Video Conference. The company has fixed September 18, 2026, as the cut-off date to determine shareholder eligibility for remote e-voting. The Register of Members and Share Transfer Books will remain closed from September 19, 2026, to September 25, 2026 (both days inclusive).

28th Annual General Meeting scheduled for September 25, 2026, at 10:00 AM via Video Conference
Cut-off date for remote e-voting eligibility set for September 18, 2026
Book closure period fixed from September 19, 2026, to September 25, 2026 (both days inclusive)

💡 Shareholders holding equity shares as of the September 18, 2026 cut-off date are eligible to participate and vote on ordinary and special resolutions at the AGM.

₹30.74 Cr Fund Utilization: Jeevan Scientific Reports Zero Deviation in Preferential Issue

🟡 NEUTRAL ⭐ 4/10

REGULATORY 📅 13 Aug 2026, 03:34 PM

Jeevan Scientific Technology has confirmed zero deviation in the utilization of ₹30.74 crore raised through a preferential allotment on January 2, 2026. As of the quarter ended June 30, 2026, the company has deployed approximately ₹14.84 crore of the total proceeds. Key spending includes ₹4.14 crore for capital expenditure and ₹3.00 crore towards the acquisition of API/formulation units. The remaining funds are earmarked for ongoing expansion, subsidiary support, and general corporate purposes as per the original objects.

Total amount raised via preferential allotment was 3074 Lakhs on January 2, 2026
Allocated 1000 Lakhs for API/formulation unit acquisitions, with 300.00 Lakhs utilized to date
Capital expenditure utilization stands at 414.46 Lakhs against a 500 Lakhs budget
Deployed 300.53 Lakhs for subsidiary working capital and capital expenditure requirements
General corporate purposes utilized 189.04 Lakhs out of an allocated 724 Lakhs

💡 Monitor the progress of the API/formulation unit acquisition, as 700 Lakhs of the allocated 1000 Lakhs remains unspent and represents a key growth driver.

Jeevan Scientific Re-appoints WTD at Rs 48 Lakh Salary; Subsidiary Posts Rs 1.01 Cr Q1 Loss

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 13 Aug 2026, 03:15 PM

Jeevan Scientific Technology Limited has approved the re-appointment of Mrs. Snigdha Mothukuri as Whole Time Director for a 3-year term starting November 2026, with an annual remuneration of Rs 48 lakhs. The board also extended the tenure of Mr. Nageswar Rao Yarllagadda beyond the age of 70. Financially, while the full consolidated results were approved, the auditor's report highlights that subsidiary Nayas Laboratories Private Limited recorded a net loss of Rs 1.01 crore on revenues of Rs 1.37 crore for the quarter ended June 30, 2026. The company's Annual General Meeting is scheduled for September 25, 2026.

Re-appointment of Mrs. Snigdha Mothukuri as Whole Time Director for 3 years at Rs 48,00,000 per annum.
Subsidiary Nayas Laboratories reported a net loss of Rs 100.94 lakhs for the quarter ended June 30, 2026.
Subsidiary revenue for Q1 FY27 stood at Rs 137.20 lakhs, indicating a high loss-to-revenue ratio.
Mr. Nageswar Rao Yarllagadda re-appointed as WTD for 3 years from June 2027 at Rs 15,00,000 per annum.
Annual General Meeting (AGM) for FY 2025-26 scheduled for September 25, 2026.

💡 Investors should review the full Q1 FY27 financial statements to assess the impact of the subsidiary's loss on consolidated margins and monitor the recent decline in promoter holding from 38.05% to 30.25%.

Rs 1.01 Cr Q1 Loss at Subsidiary; Jeevan Scientific Approves Director Re-appointments

🔵 WATCH ⭐ 6/10

EARNINGS 📅 13 Aug 2026, 03:01 PM

Jeevan Scientific Technology approved its Q1 FY27 results, highlighting a challenging quarter for its subsidiary, Nayas Laboratories. The subsidiary reported a net loss of Rs 1.01 cr on revenues of Rs 1.37 cr, which is significant given the parent company's total FY26 PAT was only Rs 1.03 cr. The board also proposed the re-appointment of Snigdha Mothukuri as Whole Time Director with a remuneration of Rs 48 lakhs per annum. Additionally, the company scheduled its AGM for September 25, 2026, to seek shareholder approval for these leadership roles.

Subsidiary Nayas Laboratories reported a net loss of Rs 100.94 lakhs for the quarter ended June 30, 2026.
Subsidiary revenue for Q1 FY27 stood at Rs 137.20 lakhs.
Proposed re-appointment of Snigdha Mothukuri as WTD for 3 years at a remuneration of Rs 48,00,000 per annum.
Promoter holding has significantly declined from 38.05% in Dec 2025 to 30.25% in Mar 2026.
Annual General Meeting (AGM) for FY 2025-26 scheduled for September 25, 2026.

💡 Investors should scrutinize the full consolidated financial statement to assess if the parent company's core operations can offset the subsidiary's losses. Monitor the AGM outcomes regarding director remuneration, which appears high relative to the company's annual net profit.

Jeevan Scientific Re-appoints Directors; Subsidiary Reports ₹1.01 Cr Loss in Q1

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 13 Aug 2026, 02:56 PM

Jeevan Scientific Technology approved its Q1 FY27 financial results and several key management re-appointments. A critical highlight is the performance of its subsidiary, Nayas Laboratories, which reported a net loss of ₹1.01 Cr on revenue of ₹1.37 Cr for the quarter ended June 2026. The board re-appointed Snigdha Mothukuri as Whole Time Director for 3 years at an annual remuneration of ₹48 lakhs. The company's Annual General Meeting (AGM) is scheduled for September 25, 2026.

Subsidiary Nayas Laboratories reported a net loss of ₹100.94 lakhs for the quarter ended June 30, 2026
Snigdha Mothukuri re-appointed as Whole Time Director for 3 years at ₹48,00,000 per annum
Nageswar Rao Yarllagadda re-appointed as Whole Time Director for 3 years at ₹15,00,000 per annum
Subsidiary revenue for Q1 FY27 stood at ₹137.20 lakhs
Annual General Meeting scheduled for September 25, 2026, via video conferencing

💡 Investors should review the full Q1 FY27 standalone results to determine if the parent company's operations are sufficient to cover the subsidiary's losses. Monitor the upcoming AGM for shareholder approval of director remunerations and leadership continuity.

Jeevan Scientific Board Meeting on Aug 13, 2026, to Approve Q1 FY27 Results

🟡 NEUTRAL ⭐ 3/10

BOARD_MEETING 📅 10 Aug 2026, 06:19 PM

Jeevan Scientific Technology has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026. The board will also finalize the date and notice for the 28th Annual General Meeting (AGM) for FY 2025-26. This follows a fiscal year where the company reported TTM revenue of Rs 62 Cr and a marginal PAT of Rs 1 Cr. Investors will be looking for a continuation of the revenue growth seen in the previous two quarters.

Board meeting scheduled for August 13, 2026, to review Q1 FY27 results
Meeting will finalize details for the 28th Annual General Meeting for FY 2025-26
Company reported TTM revenue of Rs 62 Cr with an operating profit margin of 15.9%
Quarterly revenue grew from Rs 8.8 Cr in June 2025 to Rs 21.29 Cr in March 2026
Promoter holding recently decreased from 38.05% to 30.25% as of March 2026

💡 Monitor the financial results on August 13 to assess if the company can maintain its recent quarterly revenue momentum and improve its thin net profit margins.

18.8% Capacity Expansion: Jeevan Scientific Receives CDSCO Approval for Hyderabad BA/BE Center

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 01 Aug 2026, 06:57 PM

Jeevan Scientific Technology has received CDSCO approval to increase its bed capacity at the Hyderabad Bioavailability/Bioequivalence (BA/BE) center. The total capacity will rise from 138 beds (132 general + 6 ICU) to 164 beds (156 general + 8 ICU), representing an 18.8% increase in operational infrastructure. This approval follows a successful regulatory inspection conducted on June 24, 2026. Given the company's TTM revenue of Rs 62 Cr and recent return to profitability in FY26 (PAT Rs 1.03 Cr), this expansion provides a clear pathway for volume-driven growth.

Total bed capacity increased from 138 to 164, a net addition of 26 beds
ICU bed capacity enhanced by 33%, moving from 6 to 8 beds
CDSCO regulatory inspection successfully cleared on June 24, 2026
Expansion located at the existing Balanagar, Hyderabad facility
Capacity boost of 18.8% directly supports higher volume for BA/BE studies

💡 Investors should monitor the revenue growth in the clinical research segment over the next two quarters to verify if the 18.8% capacity increase leads to a corresponding improvement in the top line and OPM (currently 15.9%).

Zero 483s: Jeevan Scientific Successfully Completes USFDA Inspection of Hyderabad Facility

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 24 Jul 2026, 12:17 PM

Jeevan Scientific Technology (JSTL) has successfully completed a USFDA inspection of its Bioanalytical Facility in Hyderabad with zero observations (No Form 483). The inspection, conducted from July 20 to July 24, 2026, reviewed BA/BE studies and operational systems. This clean report is a significant regulatory milestone for a company with TTM revenue of Rs 62 Cr, as it validates their compliance for international markets. The successful audit ensures the facility can continue supporting global clinical research projects without regulatory hurdles.

Inspection concluded with Zero 483 observations, indicating full compliance with USFDA standards.
The audit was conducted over a 5-day period from July 20, 2026, to July 24, 2026.
Facility inspected is the Bioanalytical Facility located at Manikonda, Hyderabad.
Company reported a significant revenue jump to Rs 21.29 Cr in Mar 2026 vs Rs 8.8 Cr in Jun 2025, making regulatory stability crucial.

💡 Monitor if this regulatory clearance translates into new contract wins from international pharmaceutical clients. Investors should also watch the promoter holding trend, which recently decreased from 38.05% to 30.25%.

View All 538837 Announcements on Live Market Tracking →